Terrific column, Howard. My BIL has had prostate cancer for more than 20 years and is just now entering the endgame. Your free CME will benefit many men in the next generation! Thank you!
While the economic potential for a screening tool drives much of the biomarker development, fewer tools have been developed for following those doing active surveillance or monitoring for BCR. Hopefully study design will look to validate each of these biomarker applications. It will be important to understand clearly the validated indications rather than simply assuming the test can be more broadly adopted.
Terrific column, Howard. My BIL has had prostate cancer for more than 20 years and is just now entering the endgame. Your free CME will benefit many men in the next generation! Thank you!
Thanks, Mariann. My focus here is on low-risk PCa. If your BIL is interested I can find him Substacks for men with more advanced PCa. Howard
While the economic potential for a screening tool drives much of the biomarker development, fewer tools have been developed for following those doing active surveillance or monitoring for BCR. Hopefully study design will look to validate each of these biomarker applications. It will be important to understand clearly the validated indications rather than simply assuming the test can be more broadly adopted.